Prostate cancer is the second most prevalent malignancy in men. Biomarkers for outcome
prediction are urgently needed, so that high‐risk patients could be monitored more closely …

Prostate cancer is a clinically heterogeneous disease, with some men having indolent
disease that can safely be observed, while others have aggressive, lethal disease. Over the …

Increasing evidence suggests the presence of minor cell subpopulations in prostate cancer
that are androgen independent and poised for selection as dominant clones after androgen …

BACKGROUND Despite advances in screening and local therapy, prostate cancer remains
the second most common cause of cancer related death among American men, with those …

Epigenetic processes govern prostate cancer (PCa) biology, as evidenced by the
dependency of PCa cells on the androgen receptor (AR), a prostate master transcription …

To catalog protein-altering mutations that may drive the development of prostate cancers
and their progression to metastatic disease systematically, we performed whole-exome …

Background Risk stratification or progression in prostate cancer is performed with the
support of clinical-pathological data such as the sum of the Gleason score and serum levels …

While mutations affecting protein-coding regions have been examined across many
cancers, structural variants at the genome-wide level are still poorly defined. Through …

The current paradigm of cancer care relies on predictive nomograms which integrate
detailed histopathology with clinical data. However, when predictions fail, the consequences …

We used clinical tissue from lethal metastatic castration-resistant prostate cancer (CRPC)
patients obtained at rapid autopsy to evaluate diverse genomic, transcriptomic, and …